- Trials with a EudraCT protocol (574)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
574 result(s) found for: MASS syndrome.
Displaying page 4 of 29.
| EudraCT Number: 2012-002073-60 | Sponsor Protocol Number: | Start Date*: 2012-11-30 | |||||||||||
| Sponsor Name:University of Warwick | |||||||||||||
| Full Title: Liraglutide in PCOS (LIPOS) Study: Evaluation of the Efficacy of Liraglutide on Menstrual Cyclicity in Women with PCOS - a prospective randomised double-blind placebo-controlled study | |||||||||||||
| Medical condition: Polycystic ovary syndrome (PCOS). | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000127-12 | Sponsor Protocol Number: TM006 | Start Date*: 2022-01-03 | |||||||||||
| Sponsor Name:Saniona A/S | |||||||||||||
| Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects ... | |||||||||||||
| Medical condition: Prader-Willi Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002855-85 | Sponsor Protocol Number: HO135 | Start Date*: 2016-03-18 | ||||||||||||||||
| Sponsor Name:HOVON Foundation | ||||||||||||||||||
| Full Title: A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (... | ||||||||||||||||||
| Medical condition: Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Completed) BE (Completed) LT (Prohibited by CA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-005088-30 | Sponsor Protocol Number: STOP-LEUKEMIA | Start Date*: 2021-03-26 | |||||||||||
| Sponsor Name:Kirsten Grønbæk | |||||||||||||
| Full Title: STOP-LEUKEMIA: A pilot study of metformin as a leukemia-preventive drug in patients with CCUS or LR-MDS | |||||||||||||
| Medical condition: Clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndrome (LR-MDS). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-001654-38 | Sponsor Protocol Number: TAK-861-2001 | Start Date*: 2023-05-26 | |||||||||||
| Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1) | |||||||||||||
| Medical condition: Narcolepsy with cataplexy (Narcolepsy Type 1) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) NO (Completed) FI (Completed) SE (Completed) NL (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000469-11 | Sponsor Protocol Number: 31-10-274 | Start Date*: 2011-12-15 | |||||||||||
| Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
| Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder | |||||||||||||
| Medical condition: Tourette’s Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) RO (Completed) HU (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003227-38 | Sponsor Protocol Number: EMR700623_535 | Start Date*: 2013-03-07 | ||||||||||||||||
| Sponsor Name:Merck Serono | ||||||||||||||||||
| Full Title: A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects with Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing ... | ||||||||||||||||||
| Medical condition: Anovulation in women with PCOS | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) IE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-000748-32 | Sponsor Protocol Number: SPI-62-CL-2002 | Start Date*: 2023-08-29 | |||||||||||
| Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
| Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | |||||||||||||
| Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003549-16 | Sponsor Protocol Number: Tulir 03/01 | Start Date*: 2006-03-08 | |||||||||||
| Sponsor Name:NeuroBiotec GmbH | |||||||||||||
| Full Title: Transdermal Lisuride: A double-blind, randomized, active- and placebo-controlled multi-centre phase III efficacy trial for the treatment of patients with Restless Legs Syndrome (RLS) | |||||||||||||
| Medical condition: Idiopathic and Uremic Restless Legs Syndrome (RLS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001505-93 | Sponsor Protocol Number: P11-11 | Start Date*: 2013-12-19 | |||||||||||
| Sponsor Name:Bioprojet Pharma | |||||||||||||
| Full Title: A MULTI-CENTRE, SINGLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS OF PITOLISANT (BF2.649) IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY | |||||||||||||
| Medical condition: Narcolepsy | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) FR (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-004193-39 | Sponsor Protocol Number: TAK-665-4001 | Start Date*: 2024-12-04 |
| Sponsor Name:Takeda Biopharmaceuticals India Pvt. Ltd. | ||
| Full Title: A Prospective, Multicenter, Single-arm, Open-label, Interventional Phase IV Study to Evaluate the Safety and Efficacy of Idursulfase (r-DNA Origin) (Elaprase™) in Indian Pediatric and Adult Populat... | ||
| Medical condition: Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2020-001870-32 | Sponsor Protocol Number: CDFV890D12201 | Start Date*: 2020-07-10 | |||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||
| Full Title: Phase 2, randomized, controlled, open label multi-center study to assess efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respira... | |||||||||||||
| Medical condition: COVID-19 pneumonia and impaired respiratory function | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) DK (Completed) NL (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003817-32 | Sponsor Protocol Number: LOLA-Merz:WMDHP39937 | Start Date*: 2013-01-08 | |||||||||||
| Sponsor Name:Imperial College London | |||||||||||||
| Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate | |||||||||||||
| Medical condition: Hepatic Encephalopathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002063-26 | Sponsor Protocol Number: METYX01 | Start Date*: 2013-09-08 |
| Sponsor Name:S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano | ||
| Full Title: A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma. | ||
| Medical condition: Cushing's syndrome | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003489-42 | Sponsor Protocol Number: 31-12-294 | Start Date*: 2013-03-12 | |||||||||||
| Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
| Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder | |||||||||||||
| Medical condition: Tics associated with Tourette’s Disorder in children and adolescents | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) GB (Completed) ES (Prematurely Ended) IT (Completed) DE (Ongoing) SE (Completed) NL (Ongoing) BG (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-002088-18 | Sponsor Protocol Number: H3A106104 | Start Date*: 2006-10-12 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy. | |||||||||||||
| Medical condition: Narcolepsy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) FI (Prematurely Ended) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-002053-20 | Sponsor Protocol Number: DC00065/91579 | Start Date*: 2008-09-15 | |||||||||||
| Sponsor Name:Bayer Healthcare AG | |||||||||||||
| Full Title: A 54 week treatment, randomized, multi center, double blind, placebo controlled study to assess the safety and efficacy of NEBIDO 1000 mg (4 ml) in elderly men with symptomatic late onset hypogonad... | |||||||||||||
| Medical condition: Symptomatic late onset hypogonadism | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: LV (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-010095-23 | Sponsor Protocol Number: AA-GYN-002 | Start Date*: 2009-07-06 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Omrix Biopharmaceuticals Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A prospective, controlled, randomized, multi-center, pivotal study evaluating the safety and efficacy of ADHEXIL in prevention and/or reduction of adhesions in gynecology surgery | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Adhesions in gynecology surgery. Surgeries involved will be ovarian cystectomy, endometriosis, inflammation, adhesiolysis Ovarian adhesion MedDRA 10067156 Tubal rupture MedDRA 10067553 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-005035-41 | Sponsor Protocol Number: THN102-201 | Start Date*: 2018-05-29 | |||||||||||||||||||||
| Sponsor Name:Theranexus SA | |||||||||||||||||||||||
| Full Title: SAFETY AND EFFICACY OF THN102 ON SLEEPINESS IN NARCOLEPTIC PATIENTS | |||||||||||||||||||||||
| Medical condition: This Proof-of-Concept, Phase IIa trial with THN102 should collect a sufficient body of information to assess efficacy and safety profile of THN102 versus modafinil alone in patient with a diagnosis... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2018-001203-36 | Sponsor Protocol Number: BHT-II-002 | Start Date*: 2019-01-09 | ||||||||||||||||
| Sponsor Name:4D Pharma Plc | ||||||||||||||||||
| Full Title: A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bow... | ||||||||||||||||||
| Medical condition: Irritable Bowel Syndrome (IBS), subtypes IBS-C and IBS-D | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IE (Completed) GB (Completed) PL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.